These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 9661899

  • 1. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
    Shinoda M, Kudo T, Suzuki M, Katayose Y, Sakurai N, Saeki H, Kodama H, Fukuhara K, Imai K, Hinoda Y, Matsuno S.
    Cancer Res; 1998 Jul 01; 58(13):2838-43. PubMed ID: 9661899
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
    Kodama H, Suzuki M, Katayose Y, Shinoda M, Sakurai N, Takemura S, Yoshida H, Saeki H, Ichiyama M, Tsumoto K, Asano R, Kumagai I, Imai K, Hinoda Y, Matsuno S, Kudo T.
    Cancer Immunol Immunother; 2001 Dec 01; 50(10):539-48. PubMed ID: 11776376
    [Abstract] [Full Text] [Related]

  • 4. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
    Takemura S, Kudo T, Asano R, Suzuki M, Tsumoto K, Sakurai N, Katayose Y, Kodama H, Yoshida H, Ebara S, Saeki H, Imai K, Matsuno S, Kumagai I.
    Cancer Immunol Immunother; 2002 Mar 01; 51(1):33-44. PubMed ID: 11845258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y.
    Anticancer Res; 1998 Mar 01; 18(1A):17-24. PubMed ID: 9568050
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
    Forsberg G, Skartved NJ, Wallén-Ohman M, Nyhlén HC, Behm K, Hedlund G, Nederman T.
    J Immunother; 2010 Jun 01; 33(5):492-9. PubMed ID: 20463598
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
    Okita R, Yamaguchi Y, Emi A, Matsuura K, Toge T.
    Oncol Rep; 2007 Jun 01; 17(6):1429-35. PubMed ID: 17487401
    [Abstract] [Full Text] [Related]

  • 14. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
    Chen QK, Yuan SZ.
    Zhonghua Zhong Liu Za Zhi; 1994 Sep 01; 16(5):353-5. PubMed ID: 7895586
    [Abstract] [Full Text] [Related]

  • 15. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ.
    Clin Cancer Res; 1998 Nov 01; 4(11):2859-68. PubMed ID: 9829753
    [Abstract] [Full Text] [Related]

  • 16. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
    Tordsson JM, Ohlsson LG, Abrahmsén LB, Karlström PJ, Lando PA, Brodin TN.
    Cancer Immunol Immunother; 2000 Mar 01; 48(12):691-702. PubMed ID: 10752477
    [Abstract] [Full Text] [Related]

  • 17. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
    Duan DS.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993 Mar 01; 28(5):281-3, 314. PubMed ID: 8192930
    [Abstract] [Full Text] [Related]

  • 18. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
    Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X.
    Gene Ther; 2001 Apr 01; 8(7):542-50. PubMed ID: 11319621
    [Abstract] [Full Text] [Related]

  • 19. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.
    Cancer Res; 2000 Dec 15; 60(24):6977-84. PubMed ID: 11156399
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O, Russello O, Leenen C, Diehl V, Bohlen H, Berthold F.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):185-9. PubMed ID: 11464879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.